Skip to content

Embold Therapeutics

2 viewers · 30d

Total raised

$2.5M

+$2.5M this year

1 filing since 2026 · latest SAFE filed

Cumulative raised
LAST ROUND
SAFE · $2.5M
ROUNDS
1
INVESTORS
7
FOUNDED
2023
HQ
Redwood City, CA
SECTOR
Biotech
EMPLOYEES
N/A
30D VIEWERS
2

AI overview

Updated

Embold Therapeutics is a Redwood City, California biotech developing disease-modifying treatments for genetically driven neurodegeneration, with an initial focus on Parkinson's disease. The company engineers optimized variants of human enzymes to overcome the instability and poor efficacy of the natural versions, and pairs them with a CNS delivery system. Its lead program, EMB-0141, targets glucocerebrosidase (GCase) deficiency in GBA-associated Parkinson's disease, which affects roughly 5-15% of PD patients. The company was incorporated in February 2023 and is led by founder and CEO Gjalt W. Huisman, PhD, previously a long-time enzyme-engineering leader at Codexis.

What sets it apart

Embold applies protein engineering and synthetic biology — rather than small molecules or gene therapy — to build engineered human enzyme variants that fix the stability and half-life problems of the natural enzyme, coupled with a proprietary CNS delivery technology that gets them across into the brain.

Funding history

1 round
SAFE+1Jan 21, 2026
Form D/A
+$2.5M$2.5M total

Latest SEC filings

via EDGAR · CIK 0002109643
Form D/A · Jan 21, 2026View on EDGAR

Products

1 tracked

EMB-0141

Preclinical enzyme therapeutic

Lead preclinical program: an engineered glucocerebrosidase (GCase) variant for GBA-associated Parkinson's disease, designed to overcome the instability and poor serum half-life of natural human GCase.

  • Engineered GCase variant with improved stability over the natural human enzyme
  • Improved serum half-life relative to natural GCase
  • Targets GBA-associated Parkinson's disease, roughly 5-15% of all PD patients
  • Paired with the company's B3Bold CNS delivery system

Links

WebsiteLinkedInSEC EDGAR filings